MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company aimed at developing and commercializing innovative monoclonal antibody-based therapeutics for the diagnosis of cancer, made the announcement today that the Company will issue its financial results for the 4th quarter of last year following the market closes on Thursday, February 24, 2022.
MacroGenics will conduct a conference call in order to discuss the financial results and latest corporate progress on Thursday, February 24, 2022, at 4:30 p.m. ET. The conference call can be got into by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) 5 minutes ahead of the beginning of the call and giving the Conference ID# 1067087.
The listen-only webcast of the conference call can be found under “Events & Presentations” in the Investor Relations section of the Company’s website at http://ir.macrogenics.com/events.cfm.
A recorded replay of the webcast will be available soon following the end of the call and archived on the Company’s website for a period of thirty days after the call.
About MacroGenics Inc.
MacroGenics is a biopharmaceutical company aimed at developing and commercializing innovative monoclonal antibody-based therapeutics for the diagnosis of cancer.
The Company produces its channel of product candidates preliminary from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains.
The combination of MacroGenics’ technology platforms and protein engineering expertise has enabled the Company to produce promising product candidates and step into several strategic associations with global pharmaceutical and biotechnology companies. For more information, please check the Company’s website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.